The ENRICH study examined BRII-179 as a priming therapy before administering elebsiran and PEG-IFNα.

Brii Bio announces positive end-of-treatment results from phase 2b ENRICH & ENHANCE studies to treat chronic hepatitis B: Durham, North Carolina Monday, July 6, 2026, 18:00 Hrs [I ...

DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...

Long-term eptinezumab treatment provides sustained reductions in headache burden for patients with highly refractory chronic migraine.

Why spend so much money on something that needs almost two decades to be completed? Supercarriers are far more important than you may realise ...

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure ...

Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM ...

Agentic AI workplace adoption has reached legal, finance, and recruiting teams, with new OpenAI research data showing ...

Tokenisation, new market architectures, and AI-driven trading are reshaping markets and regulatory expectations and ASIC is ...

ITU AI for Good Global Summit 2026 opens Day Zero on July 7 at Palexpo Geneva, featuring agentic AI security workshops and ...

By letting presidents fire independent agency commissioners at will, the Supreme Court broke a deliberate diffusion of power that is as old as the Constitution itself.

Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate ...